Gilteritinib (22) is indicated for the treatment of acute myeloid leukemia deriving from an FMS-like tyrosine kinase gene (FLT3) mutation detected by a companion diagnostic; it is a dual FLT3/AXL selective inhibitor [105]. Here, FLT3 is linked to acute myeloid leukemia.